author-photo

Michael Grundman

University of California, San Diego

154

Papers

17637

Citations

Citation Trend

Filter By

Papers (108) Sort By

Journal Conference Others

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

2021 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (4)
The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

2020 Alzheimer's Research & Therapy
Show All
- Source
- Cite
- Save
Citations (61)
Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review.

2020 Journal of Alzheimer's Disease
Show All
- Source
- Cite
- Save
Citations (0)
PARTICIPANT BASELINE CHARACTERISTICS IN PASSPORT, A PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF BIIB092 FOR PROGRESSIVE SUPRANUCLEAR PALSY

2019 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (4)
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial

2019 Lancet Neurology
Show All
- Source
- Cite
- Save
Citations (67)
Tau Based Therapeutics: Alternative Approaches in the War on Alzheimer’s Disease

2019
- Michael Grundman
Show All
- Source
- Cite
- Save
Citations (2)
A randomized, single ascending dose study of intravenous BIIB092 in healthy participants

2018 Alzheimer's & Dementia: Translational Research & Clinical Interventions
Show All
- Source
- Cite
- Save
Citations (44)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial

2018 JAMA Neurology
Show All
- Source
- Cite
- Save
Citations (125)
Results from a phase 1b multiple ascending-dose study of PRX002/RG7935, an Anti-alpha-synuclein monoclonal antibody, in patients with Parkinson’s disease

2018 Parkinsonism & Related Disorders
Show All
- Source
- Cite
- Save
Citations (2)
A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812

2017 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (1)